To inhibit the overexpression of USP7 in cancers, the first significant breakthrough in USP7 inhibitor development was made by Chauhan et al., who demonstrated that P5091 as a USP7 inhibitor, restricted multiple myeloma growth in MM1.S xenograft models [66]. Here, USP7 is linked to plasma cell myeloma.